Davol Rep feedback needed


Bottom line the focus is off of Arista and it continues to loose market share. The loss of contracts and the lack of focus in this area has become an issue for Arista. There is no way Progel will compete due to cost and our buyers are becoming much more cost conscious. You can get all the VATS and Dural indications you want but it won't gain much traction.


Any truth to this ?
 

Any truth to this ?

a little......Progel growth is definitely tougher with the current indication, new indications will help a lot, but won't be "block buster" growth. That said, the comment about Arista is absurd, so it's obviously coming from a competitor who has no visibility to the products performance. Arista continues on a significant upward trajectory month over month & is beating all revenue goals...hope that helps
 
What is it with the "Bard" mentality anyways? Is most of this company just full of pretentious aholes? Every Bard rep I have come accross (except for one) has been a complete douche bag.
 
a little......Progel growth is definitely tougher with the current indication, new indications will help a lot, but won't be "block buster" growth. That said, the comment about Arista is absurd, so it's obviously coming from a competitor who has no visibility to the products performance. Arista continues on a significant upward trajectory month over month & is beating all revenue goals...hope that helps

So the "new indication" is aortic use? No other vascular indication. You have no relationships in that arena either. I know that going to MM to leverage GPOs will be your thing, but how are you going to convince people to switch from what they are currently using with limited indications, minimal price difference or when going up against Baxter and J&J? I just don't see a win on this one at all.
 
pretentious? A$$holes? If you need to fill some positions, just call some Baxter biosurgery reps. Most of them are pretentious a$$holes too.
 


Write your reply...